America’s pharmaceutical pricing system has developed a peculiar—and unsustainable—definition of value. A costly medicine that cures a disease after a short course can provoke investigations, payer restrictions, and public outrage; while a less effective, continuously administered cancer drug costing several times more escapes such responses. The contrast between Gilead Sciences’ Sovaldi and Revolution Medicines’ Rasonque shows how the system resists paying for cures while accepting higher cumulative prices for treatments that extend life but do not eliminate disease.

When Sovaldi was introduced in 2013, its $1,000-per-pill price became a symbol of pharmaceutical excess. A 12-week course listed for approximately $84,000 and prompted an 18-month Senate investigation that spawned reimbursement restrictions that sometimes required hepatitis C patients to demonstrate advanced liver damage. Medicaid programs spent more than $1 billion on Sovaldi in 2014 but could treat fewer than 2.4% of enrolled patients with hepatitis C.

More than 10 years ago, I wrote in Forbes about how the controversy obscured what Sovaldi represented. Used as part of an antiviral regimen, Sovaldi (sofosbuvir) could eradicate hepatitis C in most patients, often without debilitating interferon. Depending on genotype and treatment combination, sustained virologic response rates exceeded 90%; in some studied populations, the FDA reported 97% to 100%. Sustained virologic response is considered a cure.

The cure could prevent disease transmission, cirrhosis, liver failure, liver cancer, or the need for transplantation. The $84,000 price was undeniably high, but it represented a defined course followed by the end of pharmaceutical spending for that infection. The expense was visible, immediate and concentrated—and therefore politically explosive.

Wall Street identified another problem with Sovaldi: it worked too well. Every cured patient reduced the future treatment population and the number capable of transmitting the virus. Gilead’s enormous initial sales therefore produced a shrinking market rather than durable recurring revenue.

Some analysts openly questioned cure-based business models. A Goldman Sachs biotechnology report famously asked whether curing patients was sustainable and cited Gilead’s hepatitis C franchise. Its revenue ultimately declined because patients were cured and competition increased. Wall Street still treats that experience as a warning about how quickly revenue can disappear when a therapy depletes its own market.

Using a cynical Wall Street perspective, the arithmetic is understandable. Chronic medicine produces recurring revenue; while a cure produces a sales surge followed by decline. Valuation models reward predictability, duration and repeat purchasing. But what makes sense in a spreadsheet can be perverse for society. Healthcare should want medicine to eliminate its market by eliminating disease. Instead, financial and reimbursement systems often value managing illness indefinitely.

Wall Street’s Healthcare Math

In the US, pancreatic cancer has a five-year survival rate of 13%, making it one of the highest mortality rates of all major cancers. Now consider Rasonque, (daraxonrasib). The FDA approved the daily oral drug on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma after at least one prior systemic therapy or who were not candidates for multiagent treatment. It is the first approved broad RAS inhibitor. Normal RAS genes control how cells grow and divide. In pancreatic cancer, mutations lock these proteins in a constant ‘on’ state, causing tumors to grow out of control. Daraxonrasib is the first drug to inhibit such mutations.

Daraxonrasib is a substantial medical advance. In a randomized 500-patient study, median overall survival reached 13.2 months versus 6.7 months for chemotherapy. Median progression-free survival was 7.2 months versus 3.6 months. Nearly doubling survival with an oral targeted therapy is extraordinary.

Rasonque is not a cure. The FDA recommends taking it every day until either the cancer progresses or toxicity becomes unacceptable. Its announced list price is $39,800 for a 30-day supply, translating into $477,600 for 12 months of treatment. Thirteen months of Rasonque treatment could exceed $500,000. While treatment and net costs vary, the magnitude cannot be dismissed.

Approval may be the beginning of a cancer treatment revolution because RAS mutations drive about one-third of human cancers, including nearly all pancreatic cancers, about half of colorectal cancers, and one-third of lung cancers. Rasonque inhibits multiple active forms of RAS rather than one narrow mutation, giving it potential across large tumor populations.

For Example, in previously treated RAS-mutant non-small cell lung cancer, a Phase 1/2 study produced responses across dose groups, including a 43% response rate at 160 to 220 milligrams. A global Phase 3 trial is evaluating Rasonque in metastatic RAS-mutant lung cancer. Revolution Medicines also identifies colorectal cancer as a target for its broad RAS approach.

If later studies confirm efficacy in lung, colorectal and other RAS-driven cancers, Rasonque could evolve from an important pancreatic cancer treatment into a multi-tumor oncology platform. Scientifically, that would be historic. Commercially, it could create one of the largest franchises in biotechnology. But the same success would magnify the affordability problem. A price of $39,800 per month applied to progressively larger patient populations could generate billions of dollars in annual spending, especially if patients begin treatment earlier and remain on it longer.

That possibility changes the pricing debate. A very high price may be absorbed when a drug treats a relatively small population with an immediately fatal disease. It becomes harder to sustain when indications expand into more common cancers. Earlier treatment and combination regimens might improve outcomes, but they could also extend the duration of therapy and add the costs of other drugs. The better Rasonque works across cancer, the more urgently payers will have to confront its total budget impact.

This is not an argument that Rasonque is overpriced or that patients should be denied access. I view it as an important advance against pancreatic cancer. Patients facing diseases with few effective options cannot wait for economists to perfect a pricing formula. The years of research, scientific risk and enormous capital required to drug the RAS pathway must be recognized.

The problem is that the price of innovation is being added to a healthcare system that is already becoming unaffordable. U.S. healthcare spending rose 7.2% in 2024 to $5.3 trillion, or $15,474 for every person in the country. Out-of-pocket spending alone reached $556.6 billion. CMS projects national healthcare expenditures will reach $9 trillion by 2034 and consume 20.6% of the economy.

Drug prices are only one component of the crisis. Hospital prices rose 6.7% in 2025, their largest annual increase since 2010. Families are confronting higher premiums, deductibles, and rising coinsurance rates while employers and governments struggle to finance coverage. Patients may technically have insurance and still be unable to afford what their physicians prescribe. A breakthrough that cannot be reached by the patient is a scientific success but a healthcare failure.

America’s Healthcare Values And Prices

The inconsistency in how America reacts to different forms of medical value makes the problem worse. Sovaldi’s cost arrived as one large number attached to a cure. Rasonque’s much higher cumulative cost arrives in monthly installments attached to continued treatment. Insurers are more comfortable paying recurring claims than absorbing a large upfront expenditure, even when the upfront payment may eliminate decades of future medical costs.

The fragmented insurance system compounds the problem because the organization paying for a cure today may not capture tomorrow’s savings. A commercial insurer can spend $84,000 curing a patient who changes health plans the following year. The next insurer, Medicare or Medicaid may receive the long-term benefit. This creates an incentive to delay curative treatment while reimbursing therapies whose costs can be distributed across months or years.

We need payment models that recognize the distinction between price and value without destroying the incentives that make biomedical innovation possible. Curative medicines could be financed through multiyear payments tied to durable outcomes. Payment obligations could follow patients when they change insurers. For continuously administered cancer drugs, outcomes-based agreements could connect reimbursement more directly to the duration and quality of benefit achieved. Expanded indications should also trigger renewed price negotiations as the potential market grows.

Greater transparency is essential. Patients, physicians, and policymakers need to know not simply a drug’s list price, but its expected net price, likely treatment duration and total cost relative to clinical benefit. Affordability cannot be created by dividing a half-million-dollar annual price into monthly claims. Nor should a cure automatically be labeled unaffordable merely because its total cost is paid within 12 weeks.

Sovaldi and Rasonque should not be placed in competition. One transformed hepatitis C; the other may transform not only pancreatic cancer but a broader group of RAS-driven malignancies. Both demonstrate what biotechnology can accomplish when scientists, investors and patients accept extraordinary risk. Together, however, they expose a system that can punish the economic shock of curing disease while quietly tolerating a far greater cost for managing it.

The question is not whether $84,000 or $39,800 a month sounds expensive. The question is what the patient receives, how long the benefit lasts and what future costs the treatment prevents. Unless America answers those questions consistently—and confronts the broader unaffordability of healthcare—our greatest medical advances may become products that society celebrates but that increasing numbers of patients cannot obtain.